Operator

Good morning, and welcome to the Q1 Fiscal 2026 financial results conference call for the HLS Therapeutics. At this point, I would like to turn the call over to David Mason, Investor Relations for the introductory remarks.

Dave Mason
Investor Relations Officer

Good morning, everyone, and thank you for joining us today. With me on the call is Craig Millian, Chief Executive Officer; John Hanna, Chief Financial Officer; and Brian Walsh, Chief Commercial Officer.

Earlier this morning, we issued a news release announcing our financial results for the 3 months ended March 31, 2026. This news release, along with our MD&A and financial statements, is available on our website and on SEDAR+. Please note that slides accompanying today's call can be viewed via the webcast, a link to which is available in our earnings press release and on our website on the Events page.

Certain matters discussed in today's conference call or answers that may be given to questions could constitute forward-looking statements. Actual results could differ materially from those anticipated. Risk factors that could affect results are detailed in the company's annual information form, which has been filed on SEDAR+. During the call, we will refer to adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS. Adjusted EBITDA is defined in our press release and annual filings that are available on SEDAR+ and on our website.

Please note that all financial information provided is in U.S. dollars unless otherwise specified. And I would now